The New England journal of medicine, 2021-04, Vol.384 (13), p.1191-1203
- Kelly, Ronan J
- Ajani, Jaffer A
- Kuzdzal, Jaroslaw
- Zander, Thomas
- Van Cutsem, Eric
- Piessen, Guillaume
- Mendez, Guillermo
- Feliciano, Josephine
- Motoyama, Satoru
- Lièvre, Astrid
- Uronis, Hope
- Elimova, Elena
- Grootscholten, Cecile
- Geboes, Karen
- Zafar, Syed
- Snow, Stephanie
- Ko, Andrew H
- Feeney, Kynan
- Schenker, Michael
- Kocon, Piotr
- Zhang, Jenny
- Zhu, Lili
- Lei, Ming
- Singh, Prianka
- Kondo, Kaoru
- Cleary, James M
- Moehler, Markus
2021
Details
- Autor(en) / Beteiligte
- Kelly, Ronan J
- Ajani, Jaffer A
- Kuzdzal, Jaroslaw
- Zander, Thomas
- Van Cutsem, Eric
- Piessen, Guillaume
- Mendez, Guillermo
- Feliciano, Josephine
- Motoyama, Satoru
- Lièvre, Astrid
- Uronis, Hope
- Elimova, Elena
- Grootscholten, Cecile
- Geboes, Karen
- Zafar, Syed
- Snow, Stephanie
- Ko, Andrew H
- Feeney, Kynan
- Schenker, Michael
- Kocon, Piotr
- Zhang, Jenny
- Zhu, Lili
- Lei, Ming
- Singh, Prianka
- Kondo, Kaoru
- Cleary, James M
- Moehler, Markus
- Titel
- Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
- Ist Teil von
- The New England journal of medicine, 2021-04, Vol.384 (13), p.1191-1203
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2021
- Link zum Volltext
- Quelle
- Electronic Journals Library
- Beschreibungen/Notizen
- Adjuvant chemotherapy has not improved disease-free survival among patients with resected esophageal or gastroesophageal junction cancer. In this trial, after neoadjuvant chemoradiotherapy and resection, patients with residual disease were randomly assigned to receive nivolumab or placebo. Nivolumab doubled the median disease-free survival from 11.0 to 22.4 months.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2032125Titel-ID: cdi_hal_primary_oai_HAL_hal_03217222v1
- Format
- –
- Schlagworte
- Adenocarcinoma - immunology, Adenocarcinoma - surgery, Adenocarcinoma - therapy, Adjuvant treatment, Adjuvants, Adult, Adverse events, Aged, Aged, 80 and over, B7-H1 Antigen - antagonists & inhibitors, B7-H1 Antigen - metabolism, Cancer, Cancer therapies, Carcinoma, Squamous Cell - therapy, Chemoradiotherapy, Chemoradiotherapy, Adjuvant, Chemotherapy, Adjuvant, Committees, Disease-Free Survival, Double-Blind Method, Double-blind studies, Drug therapy, Enrollments, Esophageal cancer, Esophageal Neoplasms - immunology, Esophageal Neoplasms - surgery, Esophageal Neoplasms - therapy, Esophagogastric Junction, Esophagus, Female, Humans, Immune checkpoint, Immune Checkpoint Inhibitors - adverse effects, Immune Checkpoint Inhibitors - therapeutic use, Immunotherapy, Intention to Treat Analysis, Kaplan-Meier Estimate, Life Sciences, Male, Metastasis, Middle Aged, Monoclonal antibodies, Neoadjuvant Therapy, Nivolumab - adverse effects, Nivolumab - therapeutic use, Patients, Placebos, Prognosis, Stomach Neoplasms - immunology, Stomach Neoplasms - surgery, Stomach Neoplasms - therapy, Surgery, Survival, Targeted cancer therapy